India, Aug. 15 -- Gland Pharma, Akums Drugs and Pharmaceuticals, and Kwality Pharmaceuticals all reported double-digit growth for the quarter ended June 30, 2026, making it a busy results week for the pharmaceutical CDMO sector in India.

The more intriguing question for investors is which company has the most credible growth runway ahead, even though all three exceeded revenue and profit targets. This largely depends on what each company counts as a "pipeline."

Gland Pharma has the strongest visible high-value pipeline In Q1 FY27, Gland's CDMO revenue increased 20% YoY to Rs891.5 crore; however, the more significant factor is what lies ahead. Eight ANDAs and seven 505(b)(2) filings are among the fifteen products under co-development; c...